Published in J Clin Invest on September 01, 1987
Expression of transforming growth factor-beta 1 in specific cells and tissues of adult and neonatal mice. J Cell Biol (1989) 2.77
Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc Natl Acad Sci U S A (1992) 2.54
In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J Cell Biol (1989) 2.47
Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest (1991) 2.18
Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci U S A (1988) 2.03
Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J Clin Invest (1990) 2.02
Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest (1995) 1.89
Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex. J Cell Biol (1989) 1.59
The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc Natl Acad Sci U S A (1996) 1.56
Transforming growth factor beta 1 (TGF-beta 1) induced neutrophil recruitment to synovial tissues: implications for TGF-beta-driven synovial inflammation and hyperplasia. J Exp Med (1991) 1.55
Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia. Proc Natl Acad Sci U S A (1997) 1.48
Development of gene-switch transgenic mice that inducibly express transforming growth factor beta1 in the epidermis. Proc Natl Acad Sci U S A (1999) 1.42
One systemic administration of transforming growth factor-beta 1 reverses age- or glucocorticoid-impaired wound healing. J Clin Invest (1993) 1.42
Tissue distribution of hepatopoietin-A: a heparin-binding polypeptide growth factor for hepatocytes. Proc Natl Acad Sci U S A (1990) 1.41
Transforming growth factor-beta (TGF-beta) isoforms in rat liver regeneration: messenger RNA expression and activation of latent TGF-beta. Cell Regul (1991) 1.27
Localization of transforming growth factor-beta 1 in mitochondria of murine heart and liver. Cell Regul (1991) 1.17
Transforming growth factor-beta 1 as a signal for induction of cell death by apoptosis. Br J Cancer (1993) 1.16
An alpha 2-macroglobulin receptor-dependent mechanism for the plasma clearance of transforming growth factor-beta 1 in mice. J Clin Invest (1991) 1.15
Mechanism of the cardioprotective effect of transforming growth factor beta 1 in feline myocardial ischemia and reperfusion. Proc Natl Acad Sci U S A (1993) 1.08
Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease. Am J Pathol (1990) 1.08
Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med (2007) 1.07
Mechanisms and consequences of TGF-ß overexpression by podocytes in progressive podocyte disease. Cell Tissue Res (2011) 0.98
Biliary copper excretion by hepatocyte lysosomes in the rat. Major excretory pathway in experimental copper overload. J Clin Invest (1989) 0.95
Healing of burn wounds in transgenic mice overexpressing transforming growth factor-beta 1 in the epidermis. Am J Pathol (2001) 0.91
Association between shear stress and platelet-derived transforming growth factor-β1 release and activation in animal models of aortic valve stenosis. Arterioscler Thromb Vasc Biol (2014) 0.90
Plasma TGF beta in systemic sclerosis: a cross-sectional study. Ann Rheum Dis (1994) 0.88
Combined administration of a mutant TGF-beta1/Fc and rapamycin promotes induction of regulatory T cells and islet allograft tolerance. J Immunol (2010) 0.88
Arrest of endotoxin-induced hypotension by transforming growth factor beta1. Proc Natl Acad Sci U S A (1996) 0.85
Specific binding of endocrine transforming growth factor-beta 1 to vascular endothelium. J Clin Invest (1995) 0.83
Effect of transforming growth factor Beta 1 on wound healing in induced diabetic rats. Int J Health Sci (Qassim) (2013) 0.83
Systemic administration of transforming growth factor-beta 2 prevents the impaired bone formation and osteopenia induced by unloading in rats. J Clin Invest (1995) 0.81
Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas. Br J Cancer (2000) 0.79
Increased ΤGF-β3 in primary biliary cirrhosis: an abnormality related to pathogenesis? World J Gastroenterol (2010) 0.77
Increased Smad2/3 phosphorylation in circulating leukocytes and platelet-leukocyte aggregates in a mouse model of aortic valve stenosis: Evidence of systemic activation of platelet-derived TGF-β1 and correlation with cardiac dysfunction. Blood Cells Mol Dis (2016) 0.76
A mathematical model to elucidate brain tumor abrogation by immunotherapy with T11 target structure. PLoS One (2015) 0.75
Modeling the Treatment of Glioblastoma Multiforme and Cancer Stem Cells with Ordinary Differential Equations. Comput Math Methods Med (2016) 0.75
Higher plasma transforming growth factor (TGF)-β is associated with kidney disease in older community dwelling adults. BMC Nephrol (2017) 0.75
L(59) TGF-β LAP degradation products serve as a promising blood biomarker for liver fibrogenesis in mice. Fibrogenesis Tissue Repair (2015) 0.75
Mesenchymal Stem Cells Modulate the Functional Properties of Microglia via TGF-β Secretion. Stem Cells Transl Med (2016) 0.75
Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis. Front Pharmacol (2017) 0.75
Protective effect of quercetin on liver damage induced by biliary obstruction in rats. J Mol Histol (2010) 0.75
Epidermal growth factor and a new derivative. Rapid isolation procedures and biological and chemical characterization. J Biol Chem (1972) 10.86
Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature (1985) 10.13
Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem (1983) 9.32
New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci U S A (1981) 5.89
Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science (1984) 5.20
Serum contains a platelet-derived transforming growth factor. Proc Natl Acad Sci U S A (1982) 3.88
Transforming growth factor production by chemically transformed cells. Cancer Res (1981) 3.36
Transforming growth factors from neoplastic and nonneoplastic tissues. Fed Proc (1983) 3.31
Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor beta: a proposed model for indirect mitogenesis involving autocrine activity. Proc Natl Acad Sci U S A (1986) 3.04
Specific binding to cultured cells of 125I-labeled type beta transforming growth factor from human platelets. Proc Natl Acad Sci U S A (1984) 3.01
Reversible inhibition of normal human prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serum-free medium. Cancer Res (1986) 2.83
Conversion of a high molecular weight latent beta-TGF from chicken embryo fibroblasts into a low molecular weight active beta-TGF under acidic conditions. Biochem Biophys Res Commun (1985) 2.75
Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type beta transforming growth factor. Cancer Res (1986) 1.97
Differential effects of epidermal growth factor, transforming growth factor, and insulin on DNA and protein synthesis and morphology in serum-free cultures of AKR-2B cells. Cancer Res (1984) 1.48
Inhibition of 125I-asialofetuin catabolism by leupeptin in the perfused rat liver and in vivo. J Biol Chem (1979) 1.42
The isolated perfused rat liver: conceptual and practical considerations. Hepatology (1986) 1.31
Coordinate secretion of acid hydrolases in rat bile. J Clin Invest (1979) 1.30
Subunit structure of a high-affinity receptor for type beta-transforming growth factor. Evidence for a disulfide-linked glycosylated receptor complex. J Biol Chem (1985) 1.28
Biliary secretion of fluid-phase markers by the isolated perfused rat liver. Role of transcellular vesicular transport. J Clin Invest (1985) 1.18
Receptor-mediated biliary transport of immunoglobulin A and asialoglycoprotein: sorting and missorting of ligands revealed by two radiolabeling methods. J Cell Biol (1984) 1.15
Interaction of concanavalin A and wheat germ agglutinin with the insulin receptor of fat cells and liver. J Biol Chem (1973) 1.09
Hepatic sequestration and biliary secretion of epidermal growth factor: evidence for a high-capacity uptake system. Proc Natl Acad Sci U S A (1983) 1.05
Hepatocyte handling of immunoglobulin A in the rat: the role of microtubules. Gastroenterology (1983) 1.03
Transport of epidermal growth factor by rat liver: evidence for a nonlysosomal pathway. J Cell Biol (1984) 1.01
Proteins in bile: how they get there and what they do. Am J Physiol (1984) 0.95
Effect of chloroquine on the form and function of hepatocyte lysosomes. Morphologic modifications and physiologic alterations related to the biliary excretion of lipids and proteins. Gastroenterology (1983) 0.95
Triton WR-1339, a lysosomotropic compound, is excreted into bile and alters the biliary excretion of lysosomal enzymes and lipids. Hepatology (1982) 0.94
Hepatic processing of cholecystokinin peptides. I. Structural specificity and mechanism of hepatic extraction. Am J Physiol (1986) 0.93
Biliary excretion of iron from hepatocyte lysosomes in the rat. A major excretory pathway in experimental iron overload. J Clin Invest (1986) 0.91
The mechanism of biliary excretion of alpha 1-acid glycoprotein in the rat: evidence for a molecular weight-dependent, nonreceptor-mediated pathway. Hepatology (1983) 0.90
Decreased epidermal growth factor binding in cells growth arrested in G1 by nutrient deficiency. J Cell Physiol (1981) 0.90
Hepatic processing of cholecystokinin peptides. II. Cellular metabolism, transport, and biliary excretion. Am J Physiol (1986) 0.85
Regulation of epidermal growth factor receptor number and phosphorylation by fasting in rat liver. J Biol Chem (1986) 0.85
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Biliary tract cancers. N Engl J Med (1999) 6.36
Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell (2001) 5.84
Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science (1984) 5.20
Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem (2000) 5.00
Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J Exp Med (1987) 4.35
Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol (1988) 4.34
Production and auto-induction of transforming growth factor-alpha in human keratinocytes. Nature (1987) 4.19
Serum contains a platelet-derived transforming growth factor. Proc Natl Acad Sci U S A (1982) 3.88
Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol (1990) 3.81
Trefoil peptides: less clandestine in the intestine. Science (1996) 3.60
Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology (1980) 3.57
TGF-beta 1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell (1990) 3.55
Growth factors and cancer. Cancer Res (1986) 3.48
Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development. J Cell Biol (1991) 3.38
Transforming growth factor production by chemically transformed cells. Cancer Res (1981) 3.36
A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys (1994) 3.29
Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor beta: a proposed model for indirect mitogenesis involving autocrine activity. Proc Natl Acad Sci U S A (1986) 3.04
Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J Biol Chem (2001) 3.04
Specific binding to cultured cells of 125I-labeled type beta transforming growth factor from human platelets. Proc Natl Acad Sci U S A (1984) 3.01
Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest (1997) 2.99
Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology (2000) 2.99
Reversible inhibition of normal human prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serum-free medium. Cancer Res (1986) 2.83
The cell biology of transforming growth factor beta. Biochim Biophys Acta (1990) 2.81
Cryptosporidium parvum is cytopathic for cultured human biliary epithelia via an apoptotic mechanism. Hepatology (1998) 2.75
Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest (1987) 2.74
Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. J Cell Biol (1997) 2.72
Overexpression of transforming growth factor alpha in psoriatic epidermis. Science (1989) 2.63
Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell (1990) 2.63
Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem (1999) 2.56
In situ hybridization analysis of TGF beta 3 RNA expression during mouse development: comparative studies with TGF beta 1 and beta 2. Development (1990) 2.53
Stereotactic radiosurgery for arteriovenous malformations of the brain. J Neurosurg (1991) 2.41
Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology (1989) 2.39
Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res (2000) 2.38
Current concepts. Primary sclerosing cholangitis. N Engl J Med (1984) 2.35
Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Nat Med (1997) 2.32
The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol (2000) 2.25
Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta. Mol Cell Biol (1988) 2.20
Growth modulation of mouse keratinocytes by transforming growth factors. Cancer Res (1988) 2.20
Targeted disruption of the Kvlqt1 gene causes deafness and gastric hyperplasia in mice. J Clin Invest (2000) 2.17
Transforming growth factors and the regulation of cell proliferation. Eur J Biochem (1990) 2.15
Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. Genes Dev (1993) 2.13
A new type of transforming growth factor-beta, TGF-beta 3. EMBO J (1988) 2.12
Regulation of intestinal epithelial cell growth by transforming growth factor type beta. Proc Natl Acad Sci U S A (1989) 2.09
Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol (1990) 2.09
Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci U S A (1995) 2.07
Ultrastructural studies of vasopressin effect on isolated perfused renal collecting tubules of the rabbit. J Cell Biol (1968) 2.06
Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1991) 2.06
A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A (1990) 2.03
Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci U S A (1988) 2.03
Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. Proc Natl Acad Sci U S A (1990) 2.01
Human transforming growth factor-beta 3: recombinant expression, purification, and biological activities in comparison with transforming growth factors-beta 1 and -beta 2. Mol Endocrinol (1989) 2.00
Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type beta transforming growth factor. Cancer Res (1986) 1.97
Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. Proc Natl Acad Sci U S A (1999) 1.96
Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog (1991) 1.95
Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem (1988) 1.93
Polyadenylylated RNA complementary to a mouse retrovirus-like multigene family is rapidly and specifically induced by epidermal growth factor stimulation of quiescent cells. Proc Natl Acad Sci U S A (1982) 1.89
Isolation and morphologic characterization of bile duct epithelial cells from normal rat liver. Gastroenterology (1989) 1.89
Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology (1982) 1.88
Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor alpha. Gastroenterology (1999) 1.88
Transforming growth factor beta and cell cycle regulation. Cancer Res (1995) 1.84
Monooctanoin, a dissolution agent for retained cholesterol bile duct stones: physical properties and clinical application. Gastroenterology (1980) 1.84
Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg (1991) 1.78
Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci U S A (1991) 1.77
Thrombin-induced protein phosphorylation in human platelets. J Clin Invest (1975) 1.76
Morphological, molecular, and functional heterogeneity of cholangiocytes from normal rat liver. Gastroenterology (1996) 1.76
Complex regulation of transforming growth factor beta 1, beta 2, and beta 3 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors beta 1 and beta 2. Mol Cell Biol (1989) 1.76
Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiology. Gastroenterology (1995) 1.74
Production of transforming growth factors by human colon cancer lines. Cancer Res (1986) 1.74
Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol (2000) 1.70
Localization of transforming growth factor alpha and its receptor in gastric mucosal cells. Implications for a regulatory role in acid secretion and mucosal renewal. J Clin Invest (1989) 1.69
Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology (1990) 1.69
Heterogeneity of the proliferative capacity of rat cholangiocytes after bile duct ligation. Am J Physiol (1998) 1.68
Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol (1987) 1.68
Transforming growth factors and control of neoplastic cell growth. J Cell Biochem (1987) 1.67
Comparison of intra- and extracellular transforming growth factors from nontransformed and chemically transformed mouse embryo cells. Cancer Res (1983) 1.66
Stereotactic gamma knife radiosurgery. Initial North American experience in 207 patients. Arch Neurol (1990) 1.64
Recent advances in the isolation of liver cells. Hepatology (1994) 1.63
Complications and risk factors after ileal pouch-anal anastomosis for ulcerative colitis associated with primary sclerosing cholangitis. Ann Surg (1993) 1.63
Transforming growth factor type beta regulation of actin mRNA. J Cell Physiol (1986) 1.62
Transforming growth factor alpha and beta expression in human colon cancer lines: implications for an autocrine model. Cancer Res (1987) 1.61
Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene (2001) 1.59
Differential expression of genes encoding TGFs beta 1, beta 2, and beta 3 during murine palate formation. Dev Biol (1990) 1.59
Lead ion and phosphatase histochemistry. I. Nonenzymatic hydrolysis of nucleoside phosphates by lead ion. J Histochem Cytochem (1966) 1.59
Immunodetection and modulation of cellular growth with antibodies against native transforming growth factor-beta 1. Cancer Res (1987) 1.59